---
url: https://www.servicesaustralia.gov.au/eye-proliferative-diabetic-retinopathy-andor-diabetic-macular-oedema
title: Eye - proliferative diabetic retinopathy and/or diabetic macular oedema - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:40:29.721Z
source: servicesaustralia.gov.au
---
# Eye - proliferative diabetic retinopathy and/or diabetic macular oedema

The PBS subsidises aflibercept, dexamethasone intravitreal implant and faricimab for patients with diabetic macular oedema. The PBS subsidises ranibizumab for patients with proliferative diabetic retinopathy and/or diabetic macular oedema.

## on this page

-   [Patient eligibility](#a1)
-   [Treatment specifics](#a2)
-   [Authority applications](#a3)
-   [More information](#a4)

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with aflibercept, dexamethasone intravitreal implant and faricimab under the _National Health Act 1953_, section 85 for patients with diabetic macular oedema and ranibizumab for patients with proliferative diabetic retinopathy and/or diabetic macular oedema.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing aflibercept, dexamethasone intravitreal implant, faricimab and ranibizumab.

## Treatment specifics

To be eligible for PBS-subsidised treatment with these medicines, patients must be treated by either an:

-   ophthalmologist
-   accredited ophthalmology registrar in consultation with an ophthalmologist.

## Authority applications

### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised aflibercept, dexamethasone intravitreal implant and faricimab to treat diabetic macular oedema can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

Applications for initial authority approval to prescribe PBS-subsidised ranibizumab to treat proliferative diabetic retinopathy and/or diabetic macular oedema can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

### Applying for continuing treatment

Continuing PBS-subsidised treatment with aflibercept, dexamethasone intravitreal implant, faricimab and ranibizumab is Authority Required (Streamlined). You donâ€™t need authority approval from us for the listed quantities and repeats.

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
